A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with HER2 overexpressing locally advanced or metastatic urothelial cancer.
Urothelial Carcinoma
DRUG: RC48-ADC
Objective Response Rate （ORR）as assessed by the Independent Review Committee, Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR), 24 months
Objective Response Rate（ORR）as assessed by investigator, Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR), 24 months|Progression Free Survival (PFS), PFS was defined as the time from the first administration of study treatment to the first occurrence of disease progression as determined by investigator using RECIST v1.1 or death from any cause, whichever comes first, 24 months|Duration of Objective Response (DOR), DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier, 24 months|Disease control rate (DCR), DCR was defined as the percentage of participants with a complete response (CR), partial response (PR), or stable disease (SD), 24 months|Overall survival (OS), OS was defined as the time from the first administration of study treatment to death from any cause., 24 months
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with HER2 overexpressing locally advanced or metastatic urothelial cancer.